Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Galectin Therapeutics ( (GALT) ) is now available.
On January 16, 2026, Galectin Therapeutics’ board of directors, acting on the recommendation of its compensation committee, approved cash retention bonuses for two key executives: a $300,000 bonus for Chief Medical Officer Dr. Khurram Jamil and a $150,000 bonus for Chief Financial Officer Jack Callicutt. The bonuses, structured to be paid in three equal installments on June 1, September 1, and December 1, 2026, must be repaid if either executive resigns without good reason or is terminated for cause before December 31, 2026, underscoring the company’s focus on retaining senior leadership through the end of that year.
The most recent analyst rating on (GALT) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Neutral.
The score is held down primarily by very weak financial performance (no meaningful revenue, heavy losses, negative equity, and continued cash burn with rising debt). Technicals also reflect a soft trend with negative momentum signals. Offsetting these, recent clinical/regulatory progress and insider financing support are positives but not enough to overcome the current financial risk profile.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Average Trading Volume: 545,470
Technical Sentiment Signal: Hold
Current Market Cap: $196M
Learn more about GALT stock on TipRanks’ Stock Analysis page.